VenatoRx Pharmaceuticals to Present its Lead Clinical Antibacterial Candidate, VNRX-5133, at the American Chemical Society National Meeting

By WebmasterMarch 19, 2018November 1st, 2024No Comments

VenatoRx Pharmaceuticals to Present its Lead Clinical Antibacterial Candidate, VNRX-5133, at the American Chemical Society National Meeting

Previous PostData on Cancer Resistance Pathway Inhibitor IT-139 to be Presented at AACR 2018 Annual Meeting
Next PostIntezyne Partners with Exosome Diagnostics on IT-139 Companion Diagnostic